Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06652100 · ClinicalTrials.gov registry record
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
A clinical trial of Acute Kidney Injury, sponsored by BioPorto Diagnostics.
- Active
- Registry status
- 800
- Enrollment target
- 12
- Study locations
NCT06652100: Active study of Acute Kidney Injury, sponsored by BioPorto Diagnostics.
NCT06652100 is a study of Acute Kidney Injury that is active but no longer recruiting, run by BioPorto Diagnostics. The registered enrollment target is 800 participants, below the 2,320-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (66% lower). The trial reports 12 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06652100, a study of Acute Kidney Injury, is active but no longer recruiting, sponsored by BioPorto Diagnostics.
- ACTIVE NOT RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Primary Outcome
The primary objective is to establish the cut-off value for the ProNephro AKI (NGAL) in critically ill adult patients (age 22 and older) admitted to ICU when used as an aid in risk assessment of the development of moderate to severe acute kidney injury (KDIGO stage 2/3) within 48-72 hrs. after admission.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST ProNephro AKI (NGAL)
Study Locations (12)
Alabama
- The University of Alabama - Birmingham
California
- UC Davis - Sacramento
Connecticut
- Yale University - New Haven
Illinois
- University of Chicago - Chicago
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
New Mexico
- University of New Mexico - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2026-01-31 |
What the registry record for NCT06652100 still lists
NCT06652100 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 2,320-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which ProNephro AKI (NGAL) is the first listed.
NCT06652100 lists 12 locations in 12 states (Alabama, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06652100 about?
NCT06652100 is a clinical study titled "Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults". The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
What is the current status of trial NCT06652100?
This trial is currently active not recruiting. The enrollment target is 800 participants. The study started on 2024-10-28. Estimated completion is 2026-01-31.
What conditions does trial NCT06652100 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT06652100?
The interventions under investigation include: ProNephro AKI (NGAL) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06652100?
This trial is sponsored by BioPorto Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06652100 being conducted?
This trial has 12 study locations across Alabama, California, Connecticut, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06652100's enrollment target sits among peer trials
800 15th of 74 higher than 59 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI